Air pollution may raise intrahepatic cholestasis of pregnancy risk
Exposure to high levels of fine particulate matter, or PM2.5, the most commonly studied air pollutant, and reduced time in the sunlight in the three…
Cholestasis
New PFIC3-causing mutations identified in 3 children in China
A study of three children with progressive familial intrahepatic cholestasis type 3 (PFIC3) in China revealed that different disease-causing mutations in the ABCB4 gene,…
AI model may predict cholestasis-related cognitive impairment risk
An artificial intelligence (AI) model can accurately discriminate between cholestasis patients with and without moderate to severe disease-associated cognitive impairment based on 13 possible…
American Liver Foundation gears up for advocacy summit
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…
Telling our 4-year-old that she has familial ‘tummy trouble’
I’ve often wondered how and when we’ll tell our daughter Eva that she has progressive familial intrahepatic cholestasis (PFIC), a rare liver disease. Most…
Focus of World Liver Day this April 19 is role of diet in liver health
Supporters are gearing up for World Liver Day on April 19 — marked by a global campaign to raise awareness about liver health and…
FDA approves Livmarli oral tablets for PFIC, Alagille
The U.S. Food and Drug Administration (FDA) has approved an oral tablet formulation of Livmarli (maralixibat) to treat progressive familial intrahepatic cholestasis (PFIC)…
Researchers ID mechanism behind severe ABCB11 mutations in PFIC2
Severe mutations in the ABCB11 gene cause progressive familial intrahepatic cholestasis type 2 (PFIC2) by destabilizing the resulting BSEP protein in a specific region,…
Liver tissue analysis may help ID, distinguish PFIC types: Study
Analyzing the presence of different proteins in liver tissue under a microscope can be used to help diagnose progressive familial intrahepatic cholestasis (PFIC) and…
Livmarli approved in Japan as itching treatment for Alagille, PFIC
Livmarli (maralixibat) has been approved in Japan for the treatment of itching in people with Alagille syndrome and progressive familial intrahepatic cholestasis (PFIC),…
